))
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024
Manage episode 430161162 series 2838329
Indhold leveret af VJHemOnc. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af VJHemOnc eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
The introduction of Bruton's tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the field and provided patients with a promising therapeutic option. In this podcast, you will hear from leading experts who discuss the value of these agents in MCL, sharing updates from EHA 2024.
Tune in as Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, Tycel Phillips, MD, City of Hope, Duarte, CA, Chan Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, and Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, share insights into the impact of BTK inhibitors on patient outcomes, the nuances between covalent and non-covalent BTK inhibitors, and further discuss ongoing trials evaluating these agents.
200 episoder
Del
